Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin
Topics & Concepts
MedicineHepatocellular carcinomaLenvatinibSorafenibInternal medicineGastroenterologyResponse Evaluation Criteria in Solid TumorsAdverse effectTranscatheter arterial chemoembolizationHazard ratioCarcinomaProgressive diseaseChemotherapyConfidence intervalHepatocellular Carcinoma Treatment and PrognosisVenous Thromboembolism Diagnosis and ManagementCholangiocarcinoma and Gallbladder Cancer Studies